Joe, Andrew

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,645

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 2,301

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 805

Stat3 Orchestrates Tumor Development and Progression: The Achilles Heel of Head and Neck Cancers?

Masuda, M., Wakasaki, T., Suzui, M., Toh, S., Joe, A., & Weinstein, I. (2010) · Current Cancer Drug Targets

Cytokine Signaling Pathways and InteractionsHead and Neck Cancer Studies

Cited by 60